To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting β2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations.
METHODS:
Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting β agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria.
RESULTS:
Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38–1.88, P < .001) and ipratropium (OR 2.03, 95% CI 1.34–3.07, P = .001). Tiotropium also improved dyspnea (measured with the Transitional Dyspnea Index) compared to placebo (OR 1.96, 95% CI 1.58–2.44, P < .001) and ipratropium (OR 2.10, 95% CI 1.28–3.44, P = .003). Tiotropium decreased the likelihood of an exacerbation (OR 0.83, 95% CI 0.72–0.94, P = .004) and related hospitalizations (OR 0.89, 95% CI 0.80–0.98, P = .02) but not serious adverse events (OR 1.06, 95% CI 0.97–1.17, P = .19), compared to placebo. The cumulative incidence of dry mouth was 7.4% with tiotropium, compared to 3.9% with ipratropium, 1.6% with salmeterol, and 2.0% with placebo.
CONCLUSIONS:
In stable COPD, tiotropium showed superior efficacy in improving quality of life and dyspnea, compared to placebo and ipratropium. However, tiotropium's differences with salmeterol were less clear.
PauwelsRA, RabeKF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet, 2004; 364(9434):613–620.
2.
MurrayCJ, LopezAD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997; 349(9063):1498–1504.
3.
Ai-PingC, LeeKH, LimTK. In-hospital and 5-year mortality of patients treated in the ICU for exacerbation of COPD. Chest, 1997; 128(2):518–524.
4.
DisseB, SpeckGA, RomingerKL, WitekTJJr, HammerR. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci, 1999; 64(6–7):457–464.
BarrRG, BourbeauJ, CamargoCA, RamFS. Tiotropium for stable COPD: a meta-analysis. Thorax, 2006; 61(10):854–862.
7.
RodrigoGJ, NanniniLJ. Tiotropium for the treatment of stable COPD: a systematic review with meta-analysis. Pulm Pharmacol Ther, 2007; 20(5):495–502.
8.
YohannesAM, RoomiJ, WatersK, ConnollyMJ. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med, 1998; 92(10):1231–1236.
9.
FraserDD, KeeCC, MinickP. Living with COPD: insiders' perspectives. J Adv Nurs, 2006; 55(5):550–558.
10.
CelliBR, MacNeeW. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004; 23(6):932–946.
11.
NishimuraK, IzumiT, TsukinoM, OgaT. Dyspnoea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest, 2002; 121(5):1434–1440.
12.
AlmagroP, CalboE, Ochoa de EchagüenA, BarreiroB, QuintanaS, HerediaJL, GarauJ. Mortality after hospitalization for COPD. Chest, 2002; 121(5):1441–1448.
13.
YohannesAM, BaldwinRC, ConnollyMJ. Predictors of 1-year mortality in patients discharged from hospital following exacerbation of COPD. Age Ageing, 2005; 34(5):491–496.
14.
TashkinDP, CelliB, SennS, BurkhartD, KestenS, MenjogeS, DecramerM; UPLIFT Study Investigators. A 4-year trial of triotropium in COPD. N Engl J Med, 2008; 359(15):1543–1554.
15.
JonesPW, QuirkFH, BaveystockCM, LittlejohnsP. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis, 1992; 145(6):1321–1327.
16.
MahlerDA, WeinbergDH, WellsCK, FeinsteinAR. The measurement of dyspnoea: contents, interobserver agreement, and physiologic correlates of 2 new clinical indexes. Chest, 1984; 85(6):751–758.
17.
JadadAR, MooreRA, CarrollD, JenkinsonC, ReynoldsDJ, GavaghanDJ, McQuayHJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996; 17(1):1–12.
CasaburiR, MahlerDA, JonesPW, WannerA, SanPG, ZuWallackRL, et al. A long-term evaluation of once-daily inhaled tiotropium in COPD. Eur Respir J, 2002; 19(2):217–224.
20.
VinckenW, van NoordJA, GreefhorstAP, BantjeTA, KestenS, KorduckiL, CornelissenPJ. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J, 2002; 19(2):209–216.
21.
BrusascoV, HodderR, MiravitllesM, KorduckiL, TowseL, KestenS. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 2003; 58(5):399–404.
22.
BriggsDD, CovelliH, LapidusR, BhattycharyaS, KestenS, CassinoC. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther, 2005; 18(6):397–404.
23.
CasaburiR, KukafkaD, CooperCB, WitekTJJr, KestenS. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest, 2005; 127(3):809–817.
24.
NiewoehnerDE, RiceK, CoteC, PaulsonD, CooperJAJr, KorduckiL, et al. Prevention of exacerbations of COPD with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med, 2005; 143(5):317–326.
25.
DusserD, BravoML, IaconoP. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J, 2006; 27(5):547–555.
26.
VerkindreC, BartF, AguilaniuB, FortinF, GuérinJC, Le MerreC, et al. The effect of tiotropium on hyperinflation and exercise capacity in COPD. Respiration, 2006; 73(4):420–427.
27.
ChanCK, MaltaisF, SigouinC, HaddonJM, FordGT. A randomised controlled trial to assess the efficacy of tiotropium in Canadian patients with COPD. Can Respir J, 2007; 14(8):465–472.
28.
FreemanD, LeeA, PriceD. Efficacy and safety of tiotropium in COPD patients in primary care- the SPiRiva Usual CarE (SPRUCE) study. Respir Res, 2007; 8:45.
29.
JohanssonG, LindbergA, RombergK, NordströmL, GerkenF, RoquetA. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J, 2008; 17(3):169–175.
30.
MoitaJ, BarbaraC, CardosoJ, CostaR, SousaM, RuizJ, SantosML. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther, 2008; 21(1):146–151.
31.
TonnelAB, PerezT, GrosboisJM, VerkindreC, BravoML, BrunM. Effect of tiotropium on health-related quality of life as a primary efficacy end point in COPD. Int J Chron Obstruct Pulmon Dis, 2008; 3(2):301–310.
32.
VogelmeierC, KardosP, HarariS, GansSJ, StengleinS, ThirlwellJ. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med, 2008; 102(11):1511–1520.
33.
VoshaarT, LapidusR, Maleki-YazdiR, TimmerW, RubinE, LoweL, BatemanE. A radomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med, 2008; 102(1):32–41.
34.
HalpinD, MenjogeS, VielK. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J, 2009; 18(2):106–113.
35.
RodrigoGJ, Castro-RodriguezJA, NanniniLJ, Plaza MoralV, SchiaviEA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with COPD: systematic review with meta-analysis. Respir Med, 2009; 103(10):1421–1429.
36.
SinghS, LokeYK, FurbergCD. Inhaled anticholinerigics and risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. JAMA, 2008; 300(12):1439–145.
37.
DecramerM, CelliB, KerstenS, LystigT, MehraS, TashkinDP. Effect of tiotropium on outcomes in patients with moderate COPD (UPLIFT): a prescribed subgroup analysis of a randomized controlled trial. Lancet, 2009; 374(9696):1171–1178.
